A 52-Week Study of the Efficacy of Rivastigmine in Patients with Mild to Moderately Severe Alzheimer’s Disease
Abstract
The efficacy of a centrally active cholinesterase inhibitor, rivastigmine tartrate (ENA 713; Exelon®), in patients with mild to moderately severe Alzheimer’s disease was evaluated in a 26-week open-label extension of a 26-week, double-blind, placebo-controlled study. By 52 weeks, patients originally treated with 6–12 mg/day rivastigmine had significantly better cognitive function than patients originally treated with placebo.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Patients who started an acetylcholinesterase inhibitor 6 months later showed more rapid cognitive decline than those who started the drug immediately.
“Initiation of AChEI treatment as soon as possible after the diagnosis is preferred as patients who started the AChEI 6 months later showed more rapid cognitive decline than those who started the drug immediately.17”
From Current and Future Treatments in Alzheimer Disease: An Update (2020) · cites this paper as [17]
Cites
A new rating scale for Alzheimer's disease
(1984) · American Journal of Psychiatry · doi:10.1176/ajp.141.11.1356 · Cited by 4,175 · see citing works
Rosler, M., Anand, R., Cicin-Sain, A., Gauthier, S., Agid, Y., Dal-Bianco, P., Stahelin, H. B., Hartman, R., Gharabawi, M., & Bayer, T. (1999) · BMJ · doi:10.1136/bmj.318.7184.633 · Cited by 943 · see citing works
Self-citationCholinergic Markers in Elderly Patients With Early Signs of Alzheimer Disease
Davis, K. L. (1999) · JAMA · doi:10.1001/jama.281.15.1401 · Cited by 492 · see citing works
Corey-Bloom, J. (1998) · Medical Entomology and Zoology · Cited by 467 · see citing works
(1994) · American Journal of Psychiatry · doi:10.1176/ajp.151.3.390 · Cited by 408 · see citing works
Enz, A., Amstutz, R., Boddeke, H. W. G. M., Gmelin, G., & Malanowski, J. (1993) · Progress in brain research · doi:10.1016/s0079-6123(08)62429-2 · Cited by 301 · see citing works
Dose-dependent CSF acetylcholinesterase inhibition by SDZ ENA 713 in Alzheimer's disease
Cutler, N. R., Polinsky, R. J., Srarnek, J. J., Enz, A., Jhee, S. S., Mancione, L., Hourani, J., & Zolnouni, P. (2009) · Acta Neurologica Scandinavica · doi:10.1111/j.1600-0404.1998.tb00645.x · Cited by 123 · see citing works
Slowing the progression of Alzheimer disease: methodologic issues.
Leber, P. D. (1997) · PubMed · Cited by 98 · see citing works
Observations and Suggestions on Antidementia Drug Development
Leber, P. D. (1996) · Alzheimer Disease & Associated Disorders · doi:10.1097/00002093-199601031-00009 · Cited by 87 · see citing works
Clinical predictors of course for Alzheimer patients in a longitudinal study: a preliminary report.
Kramer‐Ginsberg, E., Mohs, R. C., Aryan, M., Lobel, D., Silverman, J. M., Davidson, M., & Davis, K. L. (1988) · PubMed · Cited by 83 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
The cholinergic system in the pathophysiology and treatment of Alzheimer’s disease
Hampel, H., Mesulam, M.-M., Cuello, A. C., Farlow, M. R., Giacobini, E., Grossberg, G. T., Khachaturian, A. S., Vergallo, A., Cavedo, E., Snyder, P. J., et al. (2018) · Brain · doi:10.1093/brain/awy132 · Cited by 1,918 · see citing works
Self-citationCurrent and Future Treatments in Alzheimer Disease: An Update
Yiannopoulou, K. G., & Papageorgiou, S. G. (2020) · Journal of Central Nervous System Disease · doi:10.1177/1179573520907397 · Cited by 966 · see citing works
Neurobiology of butyrylcholinesterase
Darvesh, S., Hopkins, D. A., & Geula, C. (2003) · Nature reviews. Neuroscience · doi:10.1038/nrn1035 · Cited by 896 · see citing works
A 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate AD
Winblad, B. G., Engedal, K., Soininen, H. S., Verhey, F. R. J., Waldemar, G., Wimo, A. B., Wetterholm, A.-L., Zhang, R., Haglund, A., Subbiah, P., et al. (2001) · Neurology · doi:10.1212/wnl.57.3.489 · Cited by 721 · see citing works
Current and future treatments for Alzheimer's disease
Yiannopoulou, K. G., & Papageorgiou, S. G. (2013) · Therapeutic Advances in Neurological Disorders · doi:10.1177/1756285612461679 · Cited by 677 · see citing works
Targeting acetylcholinesterase and butyrylcholinesterase in dementia
Lane, R. M., Potkin, S. G., & Enz, A. (2005) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145705005833 · Cited by 654 · see citing works
Raina, P., Santaguida, P., Ismaila, A., Patterson, C., Cowan, D., Levine, M., Booker, L., & Oremus, M. (2008) · Annals of Internal Medicine · doi:10.7326/0003-4819-148-5-200803040-00009 · Cited by 771 · see citing works
The Alzheimer’s Disease Clinical Spectrum
Atri, A. (2019) · Medical Clinics of North America · doi:10.1016/j.mcna.2018.10.009 · Cited by 623 · see citing works
A 1-year, placebo-controlled preservation of function survival study of donepezil in AD patients
Mohs, R. C., Doody, R. S., Morris, J. C., Ieni, J. R., Rogers, S. L., Perdomo, C. A., Pratt, R. D., & for the “312” Study Group (2001) · Neurology · doi:10.1212/wnl.57.3.481 · Cited by 500 · see citing works
Doody, R. S., Si, G., Sano, M. C., Thomas, R. G., Aisen, P. S. S., Бачурин, С. О., Seely, L., & Hung, D. S.-Y. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61074-0 · Cited by 460 · see citing works
Persson, I., & Savulescu, J. (2008) · Journal of Applied Philosophy · doi:10.1111/j.1468-5930.2008.00410.x · Cited by 416 · see citing works
Cholinesterase Inhibitors for the Treatment of Alzheimer's Disease:
Grossberg, G. T. (2003) · Current Therapeutic Research · doi:10.1016/s0011-393x(03)00059-6 · Cited by 384 · see citing works
Cholinesterase Inhibitors Used in the Treatment of Alzheimer???s Disease
Wilkinson, D. G., Francis, P. T., Schwam, E. M., & Payne-Parrish, J. (2004) · Drugs & Aging · doi:10.2165/00002512-200421070-00004 · Cited by 365 · see citing works
Gold, M., Alderton, C., Zvartau-Hind, M., Egginton, S., Saunders, A. M., Irizarry, M., Craft, S., Landreth, G., Linnamägi, Ü., & Sawchak, S. (2010) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000318845 · Cited by 361 · see citing works
Current Pharmacotherapy for Alzheimer's Disease
Lleó, A., Greenberg, S. M., & Growdon, J. H. (2005) · Annual Review of Medicine · doi:10.1146/annurev.med.57.121304.131442 · Cited by 346 · see citing works
Lilienfeld, S. (2002) · CNS Drug Reviews · doi:10.1111/j.1527-3458.2002.tb00221.x · Cited by 309 · see citing works
Current and future treatments in Alzheimer’s disease
Atri, A. (2019) · Seminars in Neurology · doi:10.1055/s-0039-1678581 · Cited by 309 · see citing works
Efficacy and safety of cholinesterase inhibitors in Alzheimer's disease: a meta-analysis.
Lanctôt, K. L., Herrmann, N., Yau, K. K., Khan, L. R., Liu, B. A., Loulou, M., & Einarson, T. R. (2003) · PubMed Central · Cited by 303 · see citing works
Benefits of cognitive-motor intervention in MCI and mild to moderate Alzheimer disease
Olazarán, J., Muñiz, R., Reisberg, ., Peña‐Casanova, J., del Ser, T., Cruz-Jentoft, A. J., Serrano, P., Navarro, E., de la Rocha, M. L. G., Frank, A., et al. (2004) · Neurology · doi:10.1212/01.wnl.0000147478.03911.28 · Cited by 294 · see citing works
Cholinesterase Inhibitors for Alzheimer??s Disease
Grutzendler, J., & Morris, J. C. (2001) · Drugs · doi:10.2165/00003495-200161010-00005 · Cited by 270 · see citing works
Lopez, O. L., Becker, J. T., Wahed, A. S., Saxton, J., Sweet, R. A., Wolk, D. A., Klunk, W., & DeKosky, S. T. (2009) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.2008.158964 · Cited by 266 · see citing works
Advances in the Treatment of Alzheimer’s Disease: Benefits of Dual Cholinesterase Inhibition
Ballard, C. G. (2002) · European Neurology · doi:10.1159/000047952 · Cited by 261 · see citing works
PHARMACEUTICAL BENEFITS ADVISORY COMMITTEE
(1958) · The Medical Journal of Australia · doi:10.5694/j.1326-5377.1958.tb58406.x · Cited by 255 · see citing works
Recent advances on drug development and emerging therapeutic agents for Alzheimer’s disease
Athar, T., Balushi, K. A. A., & Khan, S. A. (2021) · Molecular Biology Reports · doi:10.1007/s11033-021-06512-9 · Cited by 261 · see citing works
Delivery of peptide and protein drugs over the blood–brain barrier
Brasnjevic, I., Steinbusch, H. W. M., Schmitz, C., & Martinez-Martinez, P. (2009) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2008.12.002 · Cited by 279 · see citing works
Hashimoto, M., Kazui, H., Matsumoto, K., Nakano, Y., Yasuda, M., & Mori, E. (2005) · American Journal of Psychiatry · doi:10.1176/appi.ajp.162.4.676 · Cited by 243 · see citing works
Long-term course and effectiveness of combination therapy in Alzheimer disease
Atri, A., Shaughnessy, L. W., Locascio, J. J., & Growdon, J. H. (2008) · Alzheimer Disease & Associated Disorders · doi:10.1097/wad.0b013e31816653bc · Cited by 230 · see citing works
Bullock, R. A., Touchon, J., Bergman, H., Gambina, G., He, Y., Rapatz, G., Nagel, J., & Lane, R. M. (2005) · Current Medical Research and Opinion · doi:10.1185/030079905x56565 · Cited by 228 · see citing works
Pharmacologic treatments of dementia
Bonner, L. T., & Peskind, E. R. (2002) · Medical Clinics of North America · doi:10.1016/s0025-7125(02)00007-x · Cited by 225 · see citing works
CSF biomarkers predict a more malignant outcome in Alzheimer disease
Wallin, A., Blennow, K., Zetterberg, H., Londos, E., Minthon, L., & Hansson, O. (2010) · Neurology · doi:10.1212/wnl.0b013e3181dd4dd8 · Cited by 223 · see citing works
Effective Pharmacologic Management of Alzheimer’s Disease
Farlow, M. R., & Cummings, J. L. (2007) · The American Journal of Medicine · doi:10.1016/j.amjmed.2006.08.036 · Cited by 225 · see citing works
Self-citationDonepezil treatment of patients with MCI
Doody, R. S., Ferris, S. H., Salloway, S., Sun, Y., Goldman, R. S., Watkins, W. E., Xu, Y., & Murthy, A. K. (2009) · Neurology · doi:10.1212/01.wnl.0000344650.95823.03 · Cited by 212 · see citing works
Use of Cholinesterase Inhibitors in Clinical Practice: Evidence-Based Recommendations
Cummings, J. L. (2003) · American Journal of Geriatric Psychiatry · doi:10.1097/00019442-200303000-00004 · Cited by 202 · see citing works
DONEPEZIL TREATMENT OF PATIENTS WITH MCI: A 48-WEEK RANDOMIZED, PLACEBO- CONTROLLED TRIAL
Crane, P. K. (2009) · Neurology · doi:10.1212/wnl.0b013e3181bd6c25 · Cited by 194 · see citing works
Rizzo, S., Rivière, C., Piazzi, L., Bisi, A., Gobbi, S., Bartolini, M., Andrisano, V., Morroni, F., Tarozzi, A., Monti, J., et al. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm8002747 · Cited by 191 · see citing works
Reimagining cholinergic therapy for Alzheimer’s disease
Giacobini, E., Cuello, A. C., & Fisher, A. (2022) · Brain · doi:10.1093/brain/awac096 · Cited by 187 · see citing works
Long-term Effects of Cholinesterase Inhibitors on Cognitive Decline and Mortality
Xu, H., Garcia-Ptacek, S., Jönsson, L., Wimo, A., Nordström, P., & Eriksdotter, M. (2021) · Neurology · doi:10.1212/wnl.0000000000011832 · Cited by 182 · see citing works
Levey, A. I., Lah, J. J., Goldstein, F. C., Steenland, K., & Bliwise, D. L. (2006) · Clinical Therapeutics · doi:10.1016/j.clinthera.2006.07.006 · Cited by 180 · see citing works
3-Year Study of Donepezil Therapy in Alzheimer’s Disease: Effects of Early and Continuous Therapy
Winblad, B. G., Wimo, A. B., Engedal, K., Soininen, H. S., Verhey, F. R. J., Waldemar, G., Wetterholm, A.-L., Haglund, A., Zhang, R., & Schindler, R. J. (2006) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000091790 · Cited by 176 · see citing works
Methods to improve the detection of mild cognitive impairment
Shankle, W. R., Romney, A. K., Hara, J., Fortier, D., Dick, M. B., Chen, J., Chan, T., & Sun, X. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0501157102 · Cited by 169 · see citing works
Raskind, M. A., Peskind, E. R., Truyen, L., Kershaw, P., & Damaraju, C. V. (2004) · Archives of Neurology · doi:10.1001/archneur.61.2.252 · Cited by 167 · see citing works
McHardy, S. F., Wang, H.-Y. L., McCowen, S. V., & Valdez, M. C. (2016) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2017.1272571 · Cited by 162 · see citing works
Cholinesterase inhibitors in the treatment of dementia.
Ellis, J. M. (2005) · PubMed · Cited by 159 · see citing works
Burns, A. S., & O'Brien, J. T. (2006) · Journal of Psychopharmacology · doi:10.1177/0269881106068299 · Cited by 157 · see citing works
Acetylcholinesterase and Its Inhibition in Alzheimer Disease
Lane, R. M., Kivipelto, M., & Greig, N. H. (2004) · Clinical Neuropharmacology · doi:10.1097/00002826-200405000-00011 · Cited by 149 · see citing works
Bakchine, S., & Loft, H. (2007) · Journal of Alzheimer s Disease · doi:10.3233/jad-2007-11409 · Cited by 136 · see citing works
Animal models of Alzheimer disease: historical pitfalls and a path forward
Cavanaugh, S. E. (2014) · ALTEX · doi:10.14573/altex.1310071 · Cited by 132 · see citing works
Pharmacotherapy of Alzheimer's disease: is there a need to redefine treatment success?
Winblad, B. G., Brodaty, H., Gauthier, S. G., Morris, J. C., Orgogozo, J., Rockwood, K. J., Schneider, L. S. S., Takeda, M., Tariot, P. N., & Wilkinson, D. G. (2001) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.496 · Cited by 126 · see citing works
A review of rivastigmine: A reversible cholinesterase inhibitor
Williams, B. R., Nazarians, A., & Gill, M. A. (2003) · Clinical Therapeutics · doi:10.1016/s0149-2918(03)80160-1 · Cited by 122 · see citing works
Current therapeutic targets for the treatment of Alzheimer’s disease
Grill, J. D., & Cummings, J. L. (2010) · Expert Review of Neurotherapeutics · doi:10.1586/ern.10.29 · Cited by 121 · see citing works
Kawas, C. H. (2003) · New England Journal of Medicine · doi:10.1056/nejmcp022295 · Cited by 114 · see citing works
Feldman, H., Gauthier, S. G., Hecker, J. R., Vellas, B. J., Xu, Y., Ieni, J. R., & Schwam, E. M. (2005) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.1325 · Cited by 110 · see citing works
Management of Alzheimer's Disease
Grossberg, G. T., & Desai, A. K. (2003) · The Journals of Gerontology Series A · doi:10.1093/gerona/58.4.m331 · Cited by 110 · see citing works
Economic considerations in the management of Alzheimer's disease
Zhu, C. W., & Sano, M. (2006) · Clinical Interventions in Aging · doi:10.2147/ciia.2006.1.2.143 · Cited by 108 · see citing works
Long-term effects of rivastigmine in moderately severe Alzheimer's disease
Doraiswamy, P. M., Krishnan, K., Anand, R., Sohn, H., Danyluk, J., Hartman, R. D., & Veach, J. (2002) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/s0278-5846(01)00326-8 · Cited by 108 · see citing works
Self-citationRivastigmine in subcortical vascular dementia
Moretti, R., Torre, P., Antonello, R. M., Cazzato, G., & Bava, A. (2002) · Journal of the Neurological Sciences · doi:10.1016/s0022-510x(02)00280-0 · Cited by 107 · see citing works
Feldman, H., van Baelen, B., Kavanagh, S. M., & Torfs, K. (2005) · Alzheimer Disease & Associated Disorders · doi:10.1097/01.wad.0000157065.43282.bc · Cited by 106 · see citing works
López, O. L., Becker, J. T., Saxton, J. A., Sweet, R. A., Klunk, W. E., & DeKosky, S. T. (2004) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.2005.53015.x · Cited by 105 · see citing works
Babiloni, C., Pandis, M. F. D., Vecchio, F., Buffo, P., Sorpresi, F., Frisoni, G. B., & Rossini, P. M. (2011) · Clinical Neurophysiology · doi:10.1016/j.clinph.2011.03.029 · Cited by 104 · see citing works
A Clinical Overview of Cholinesterase Inhibitors in Alzheimer’s Disease
Farlow, M. R. (2002) · International Psychogeriatrics · doi:10.1017/s1041610203008688 · Cited by 100 · see citing works
Self-citationCorey‐Bloom, J. (2002) · International Psychogeriatrics · doi:10.1017/s1041610203008664 · Cited by 97 · see citing works
Babiloni, C., Lizio, R., Percio, C. D., Marzano, N., Soricelli, A., Salvatore, E., Ferri, R., Cosentino, F., Tedeschi, G., Montella, P., et al. (2013) · Journal of Alzheimer s Disease · doi:10.3233/jad-121750 · Cited by 99 · see citing works
Cerebral blood flow and cognitive responses to rivastigmine treatment in Alzheimer’s disease
Venneri, A., Shanks, M. F., Staff, R. T., Pestell, S. J., Forbes‐McKay, K., Gemmell, H. G., & Murray, A. D. (2002) · Neuroreport · doi:10.1097/00001756-200201210-00020 · Cited by 98 · see citing works
Effectiveness of antidementia drugs in delaying Alzheimer's disease progression
Rountree, S. D., Atri, A., Lopez, O. L., & Doody, R. S. (2013) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2012.01.002 · Cited by 97 · see citing works
Wilkinson, D., Stave, C., Keohane, D. J., & Vincenzino, O. (2004) · Journal of International Medical Research · doi:10.1177/147323000403200207 · Cited by 97 · see citing works
Fillit, H. M., Hill, J. W., & Futterman, R. (2002) · PubMed · Cited by 92 · see citing works
Jacobsen, J. S., Reinhart, P. H., & Pangalos, M. N. (2005) · NeuroRx · doi:10.1602/neurorx.2.4.612 · Cited by 92 · see citing works
Evaluation of Rivastigmine in Alzheimer’s Disease
Nguyen, K. T., Hoffman, H. L., Chakkamparambil, B., & Grossberg, G. T. (2020) · Neurodegenerative Disease Management · doi:10.2217/nmt-2020-0052 · Cited by 89 · see citing works
Bakchine, S., & Loft, H. (2008) · Journal of Alzheimer s Disease · doi:10.3233/jad-2008-13110 · Cited by 88 · see citing works
Bullock, R. M., & Dengiz, A. (2005) · International Journal of Clinical Practice · doi:10.1111/j.1368-5031.2005.00562.x · Cited by 87 · see citing works
Defining optimal treatment with cholinesterase inhibitors in Alzheimer's disease
Small, G. W., & Bullock, R. A. (2010) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2010.03.016 · Cited by 83 · see citing works
Neuroprotective strategies in Alzheimer’s disease
Longo, F. M., & Massa, S. M. (2004) · NeuroRx · doi:10.1602/neurorx.1.1.117 · Cited by 83 · see citing works
Nicotinic acetylcholine receptors: an overview on drug discovery
D’hoedt, D., & Bertrand, D. (2009) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728220902841045 · Cited by 79 · see citing works
Stefanova, E. D., Wall, A., Almkvist, O., Nilsson, A., Forsberg, A., Långström, B., & Nordberg, A. K. (2005) · Journal of Neural Transmission · doi:10.1007/s00702-005-0312-6 · Cited by 79 · see citing works
Yanovsky, I., Finkin-Groner, E., Zaikin, A., Lerman, L., Shalom, H., Zeeli, S., Weill, T., Ginsburg, I., Nudelman, A., & Weinstock, M. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm301411g · Cited by 77 · see citing works
Current and Emerging Pharmacological Treatment Options for Dementia
Ringman, J. M., & Cummings, J. L. (2006) · Behavioural Neurology · doi:10.1155/2006/315386 · Cited by 76 · see citing works
Current Therapeutic Options for Alzheimers Disease
Lleó, A. (2007) · Current Genomics · doi:10.2174/138920207783769549 · Cited by 76 · see citing works
Kapaki, E., Paraskevas, G. P., Zalonis, I., & Zournas, C. (2003) · European Journal of Neurology · doi:10.1046/j.1468-1331.2003.00562.x · Cited by 76 · see citing works
Long-Term Treatment of Alzheimer Disease
Winblad, B. G., & Jelić, V. (2004) · Alzheimer Disease & Associated Disorders · doi:10.1097/01.wad.0000127495.10774.a4 · Cited by 76 · see citing works
The effect of telemedicine on cognitive decline in patients with dementia
Kim, H. S., Jhoo, J. H., & Jang, J. (2015) · Journal of Telemedicine and Telecare · doi:10.1177/1357633x15615049 · Cited by 75 · see citing works
Farlow, M. R., Potkin, S. G., Koumaras, B., Veach, J., & Mirski, D. F. (2003) · Archives of Neurology · doi:10.1001/archneur.60.6.843 · Cited by 72 · see citing works
Self-citationSun, Y., Lai, M., Lu, C. ‐., & Chen, R. ‐. (2008) · European Journal of Neurology · doi:10.1111/j.1468-1331.2007.02049.x · Cited by 71 · see citing works
Hameed, S., Fuh, J., Senanarong, V., Ebenezer, E. G. M., Looi, I., Dominguez, J. C., Park, K. W., Karanam, A. K., & Simon, O. (2020) · Journal of Alzheimer s Disease Reports · doi:10.3233/adr-190143 · Cited by 67 · see citing works
Rivastigmine in the treatment of patients with Alzheimer's disease
Müller, T. H. (2007) · Neuropsychiatric Disease and Treatment · doi:10.2147/nedt.2007.3.2.211 · Cited by 67 · see citing works
Han, J.-Y., Besser, L. M., Xiong, C., Kukull, W. A., & Morris, J. C. (2019) · Alzheimer Disease & Associated Disorders · doi:10.1097/wad.0000000000000291 · Cited by 66 · see citing works
Fawcett, J. R., Bordayo, E. Z., Jackson, K., Liu, H., Peterson, J., Svitak, A. L., & Frey, W. H., II (2002) · Brain Research · doi:10.1016/s0006-8993(02)02981-5 · Cited by 68 · see citing works
Karaman, Y., Erdoğan, F. F., Köseoğlu, E., Turan, T., & Ersoy, A. (2004) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000080972 · Cited by 66 · see citing works
Zhu, C. W., Livote, E. E., Scarmeas, N., Albert, M., Brandt, J., Blacker, D., Sano, M. C., & Stern, Y. (2013) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2012.09.015 · Cited by 65 · see citing works
Scharre, D. W., Chang, S. I., Nagaraja, H. N., Vrettos, N. E., & Bornstein, R. A. (2017) · Alzheimer s Research & Therapy · doi:10.1186/s13195-017-0269-3 · Cited by 63 · see citing works
Zafeiris, D., Rutella, S., & Ball, G. (2018) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2018.02.001 · Cited by 65 · see citing works
Long-Term Cholinesterase Inhibitor Treatment of Alzheimer???s Disease
Johannsen, P. (2004) · CNS Drugs · doi:10.2165/00023210-200418120-00001 · Cited by 65 · see citing works
Darreh‐Shori, T., Kadir, A., Almkvist, O., Grut, M., Wall, A., Blomquist, G., Eriksson, B., Långström, B., & Nordberg, A. K. (2006) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2006.09.020 · Cited by 63 · see citing works
Drug Persistency Patterns for Patients Treated With Rivastigmine or Donepezil in Usual Care Settings
Mauskopf, J., Paramore, C., Lee, W. C., & Snyder, E. H. (2005) · Journal of Managed Care Pharmacy · doi:10.18553/jmcp.2005.11.3.231 · Cited by 62 · see citing works
Realistic Expectations: The Management of Severe Alzheimer Disease
Bullock, R. A., & Hammond, G. (2003) · Alzheimer Disease & Associated Disorders · doi:10.1097/00002093-200307003-00004 · Cited by 61 · see citing works
Advances on Therapeutic Strategies for Alzheimer’s Disease: From Medicinal Plant to Nanotechnology
Hassan, N. A., Alshamari, A. K., Hassan, A. A., Elharrif, M. G., Alhajri, A. M., Sattam, M., & Khattab, R. R. (2022) · Molecules · doi:10.3390/molecules27154839 · Cited by 64 · see citing works
Defining the Role of the Caregiver in Alzheimer??s Disease Treatment
Brodaty, H., & Green, A. (2002) · Drugs & Aging · doi:10.2165/00002512-200219120-00001 · Cited by 60 · see citing works
Serrano‐Pozo, A., Aldridge, G. M., & Zhang, Q. (2017) · Journal of Alzheimer s Disease · doi:10.3233/jad-170184 · Cited by 58 · see citing works
Treatment Guidelines for Alzheimer's Disease
Geldmacher, D. (2007) · The Primary Care Companion to The Journal of Clinical Psychiatry · doi:10.4088/pcc.v09n0205 · Cited by 57 · see citing works
The costs of vascular dementia
Fillit, H. M., & Hill, J. W. (2002) · Journal of the Neurological Sciences · doi:10.1016/s0022-510x(02)00257-5 · Cited by 58 · see citing works
The Pharmacoeconomics of Cognitive Enhancers in Moderate to Severe Alzheimerʼs Disease
Cappell, J., Herrmann, N., Cornish, S., & Lanctôt, K. L. (2010) · CNS Drugs · doi:10.2165/11539530-000000000-00000 · Cited by 57 · see citing works
- Authors
- Farlow, M., Anand, R., Messina Jr, J., Hartman, R., & Veach, J.
- Affiliations
- Indiana University Indianapolis (US)
- Venue
- European Neurology
- Publisher
- S. Karger AG
- Published
- 2000
- Volume
- 44
- Issue
- 4
- Pages
- 236-241
- ISSN
- 0014-3022 (ISSN-L)
- 1421-9913
- OpenAlex
- W2076676029
- Cited by
- 332
- References
- 10
- Citations by year
- 2026: 6 · 2025: 6 · 2024: 7 · 2023: 9 · 2022: 10 · 2021: 8 · 2020: 6 · 2019: 7 · 2018: 5 · 2017: 5 · 2016: 8 · 2015: 4 · 2014: 3 · 2013: 9 · 2012: 7
- FWCI
- 15.52
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- European Neurology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology › Cholinesterase and Neurodegenerative Diseases
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
- Keywords
- rivastigmine, Alzheimer's disease, cholinesterase inhibitors, cognitive function, open-label extension, long-term efficacy
- MeSH terms
- Rivastigmine, Age Factors, Aged, Alzheimer Disease, Carbamates, Cholinesterase Inhibitors, Cognition, Dose-Response Relationship, Drug, Double-Blind Method, Humans, Time Factors, Treatment Outcome, Disease Progression, Phenylcarbamates
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
